FDA’s Kweder Among Witnesses At Senate Drug Safety Hearing March 1
This article was originally published in The Pink Sheet Daily
Executive Summary
The Office of New Drugs deputy director could discuss implementation of the new Drug Safety Oversight Board. Other witnesses at the Health Committee hearing include former FDA advisor Gottlieb, Zuckerman Spaeder partner Schultz.
You may also be interested in...
FDA's Woodcock To Testify Before Senate Health Committee March 3
Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.
FDA's Woodcock To Testify Before Senate Health Committee March 3
Janet Woodcock is one of two FDA representatives testifying at two days of hearings on issues related to drug safety; Sandra Kweder will testify March 1. Vertex Pharmaceuticals CEO Joshua Boger will present the pharmaceutical industry's point of view.
FDA Drug Safety Oversight Board Will Include VA, Other Agencies
The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.